https://doi.org/10.1016/s1470-2045(17)30688-5
P
Per Eystein Lønning
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
636
Papers
57.9K
Citations
74
h-index
309
i10-index
Per Eystein Lønning is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Estrogen and related hormone effects & Breast Cancer Treatment Studies & Cancer Genomics and Diagnostics. The author has an h-index of 74, co-authored 541 publications.
ORCID: 0000-0002-8890-6303Papers by this author
worksBuparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · The Lancet Oncology · 379 citations
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001 · PubMed · 328 citations
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
2020 · Annals of Oncology · 210 citations
https://doi.org/10.1016/j.annonc.2020.11.009
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
2012 · BMC Cancer · 115 citations
https://doi.org/10.1186/1471-2407-12-39
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
2018 · Breast Cancer Research · 109 citations
https://doi.org/10.1186/s13058-018-1049-0
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
2013 · BMC Cancer · 74 citations
https://doi.org/10.1186/1471-2407-13-456
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat